WO2009085360A8 - Citreamicin antibiotic with a sugar residue - Google Patents

Citreamicin antibiotic with a sugar residue Download PDF

Info

Publication number
WO2009085360A8
WO2009085360A8 PCT/US2008/078732 US2008078732W WO2009085360A8 WO 2009085360 A8 WO2009085360 A8 WO 2009085360A8 US 2008078732 W US2008078732 W US 2008078732W WO 2009085360 A8 WO2009085360 A8 WO 2009085360A8
Authority
WO
WIPO (PCT)
Prior art keywords
citreamicin
antibiotic
sugar residue
neocitreamicins
analogs
Prior art date
Application number
PCT/US2008/078732
Other languages
French (fr)
Other versions
WO2009085360A2 (en
WO2009085360A3 (en
Inventor
Aaron Peoples
Qibo Zhang
Andrew Staley
Lucy Ling
Charles Moore
Kim Lewis
Original Assignee
Novobiotic Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novobiotic Pharmaceuticals Llc filed Critical Novobiotic Pharmaceuticals Llc
Publication of WO2009085360A2 publication Critical patent/WO2009085360A2/en
Publication of WO2009085360A8 publication Critical patent/WO2009085360A8/en
Publication of WO2009085360A3 publication Critical patent/WO2009085360A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/365—Nocardia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

This application relates to novel neocitreamicins and their analogs; processes for their preparation; pharmaceutical compositions comprising these neocitreamicins; and methods of using such compounds.
PCT/US2008/078732 2007-10-04 2008-10-03 Citreamicin antibiotic with a sugar residue WO2009085360A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99767407P 2007-10-04 2007-10-04
US60/997,674 2007-10-04
US7642908P 2008-06-27 2008-06-27
US61/076,429 2008-06-27

Publications (3)

Publication Number Publication Date
WO2009085360A2 WO2009085360A2 (en) 2009-07-09
WO2009085360A8 true WO2009085360A8 (en) 2009-09-24
WO2009085360A3 WO2009085360A3 (en) 2009-11-12

Family

ID=40824969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/078732 WO2009085360A2 (en) 2007-10-04 2008-10-03 Citreamicin antibiotic with a sugar residue

Country Status (1)

Country Link
WO (1) WO2009085360A2 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224314A (en) * 1979-03-02 1980-09-23 Pfizer Inc. Antibiotics produced by species of Nocardia
US6613797B2 (en) * 1999-12-02 2003-09-02 Interlab, Inc. Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins
GB0011927D0 (en) * 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
GB0016020D0 (en) * 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
US6884604B2 (en) * 2001-03-30 2005-04-26 Sloan-Kettering Institute For Cancer Research Glycorandomization and the production of novel erythronolide and coumarin analogs
WO2007095696A1 (en) * 2006-02-27 2007-08-30 The University Of Queensland Polyketide xanthones and uses thereof

Also Published As

Publication number Publication date
WO2009085360A2 (en) 2009-07-09
WO2009085360A3 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
WO2009053854A3 (en) Polymorphs of dasatinib and process for preparation thereof
ZA200900347B (en) Preparation of pharmaceutical compositions
AU2010246749A8 (en) Thiophene derivatives
WO2010067374A3 (en) Polymorphs of dasatinib
EP2457908B8 (en) Process for the Preparation of Compounds useful as inhibitors of SGLT
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2009006590A3 (en) Docetaxel process and polymorphs
IL200854A (en) Spiro substituted compounds, methods for their preparation and pharmaceutical compositions comprising them as angiogenesis inhibitors
HK1131777A1 (en) Crystalline form vi of agomelatine, a process for its preparation and pharmaceutical compositions containing it
EP1938842A4 (en) Method for preparation of pharmaceutical composition having improved disintegradability
WO2008127646A3 (en) Transaminase-based processes for preparation of pregabalin
TW200942531A (en) Crystal forms of a nitrocatechol
WO2008155615A3 (en) An improved process for the preparation of cephalosporin antibiotic
WO2009104021A3 (en) Novel polymorphs and processes for their preparation
MY144726A (en) Diosmetin compounds, process for their preparation and pharmaceutical compositions containing them
WO2008098978A3 (en) Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
WO2010049449A3 (en) Novel salts of sunitinib
WO2010129636A3 (en) Lenalidomide polymorph
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2007118873A3 (en) Polymorphs of atorvastatin sodium and magnesium salts
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2008033935A3 (en) Vinorelbine derivatives
AU2009235968A8 (en) Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these
AU2009298305A8 (en) Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (GnRH) as immunogen
WO2009034432A8 (en) Novel compounds active as muscarinic receptor antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08866744

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08866744

Country of ref document: EP

Kind code of ref document: A2